Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.
The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd
The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.
The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.
46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why
The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.
The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.
Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India
The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share.
The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share.
From Rs 5.82 to Rs 31.96 per share in 294 days: Pharma penny stock hit 5 per cent upper circuit on March 24
The stock gave multibagger returns of 449 per cent from its 52-week low of Rs 5.82 per share.
The stock gave multibagger returns of 449 per cent from its 52-week low of Rs 5.82 per share.
Pharma Giant Expands with Strategic Acquisition in Singapore
The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations.
The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.
Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19
The stock gave multibagger returns of 160 per cent in just 1 year whereas BSE Sensex Index is up by 5 per cent.
The stock’s 52-week high is Rs 1,678.60 per share while its 52-week low is Rs 489.20 per share.
Pharma Penny Stock Under Rs 50 in Green After Signing an MoU with Indian Navy (INS Kalinga)
The company has a market cap of over Rs 1,200 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
From Rs 34.51 per share (52-week low) to Rs 38.29 per share, the stock is up by 11 per cent.
Strategic Acquisition: Major MedTech Expansion by Indian Pharma Giant
Zydus Lifesciences Limited has announced its strategic decision to acquire a controlling stake in Amplitude Surgical SA, a France-based company listed on Euronext Paris.
Zydus Lifesciences Limited, a prominent player in the Indian pharmaceutical sector, is currently trading at a stock price of Rs 900 with a market capitalization of over Rs 90,000 crores.
New Diabetes Drug Launched: Affordable Treatment Revolution in India
Alkem's commitment to global health improvement is reflected in its diverse product offerings and international presence.
Alkem Laboratories Ltd. is a prominent Indian pharmaceutical company known for its high-quality medicines over the past 50 years.
From Rs 5.82 to Rs 33.49 per share: Pharma penny stock hit upper circuit on March 07
The stock gave multibagger returns of 475 per cent from its 52-week low of Rs 5.82 per share.
The stock gave multibagger returns of 475 per cent from its 52-week low of Rs 5.82 per share.
Pharma stock under Rs 70 jumps 11.5%; Unico Global Opportunities Fund bought 45,77,717 shares & Ebisu Global Opportunities Fund bought 45,21,028 shares
The company has a market cap of over Rs 300 crore and the stock is up by 24.1 per cent from its 52-week low of Rs 50.42 per share.
The company has a market cap of over Rs 300 crore and the stock is up by 24.1 per cent from its 52-week low of Rs 50.42 per share.